Реєстраційний номер
2122U008081, Матеріали видань та локальних репозитаріїв
Категорія
Текст
Назва роботи
The clinical experience of the effective use of dapagliflozin in comorbid cardiac patients with concomitant type 2 diabetes mellitus and arterial hypertension on the background of overweight in outpatient setting
Автор
Rishko Oleksandr A.
Derbak Mariya A.
Ihnatko Yaroslav Y.
Dankanych Yevheniia Е.
Bletskan Myroslava M.
Krasnova Anatolija A.
Mashura Hanna Y.
Рішко Олександр Адальбертович
Дербак Марія Антонівна
Данканич Євгенія Еміліянівна
Блецкан Мирослава Михайлівна
Краснова Анатолія Анатоліївна
Машура Ганна Юріївна
Rishko Oleksandr A.
Derbak Mariya A.
Ihnatko Yaroslav Y.
Dankanych Yevheniia E.
Bletskan Myroslava M.
Krasnova Anatolija A.
Mashura Hanna Y.
Rishko Oleksandr Adalbertovych
Derbak Mariya Antonivna
Dankanych Yevheniya Emiliyanivna
Bletskan Myroslava Mykhailivna
Krasnova Anatoliya Anatoliivna
Mashura Hanna Yuriivna
Дата публікації
01-01-2022
Постачальник інформації
Ужгородський національний університет
Першоджерело
https://dspace.uzhnu.edu.ua/jspui/handle/lib/47036
Видання
Aluna publishing hause
Опис
The normalization of blood pressure, elimination of heart failure symptoms on the background of increased ejection fraction, improved indicators of the functional
capacity of the kidneys, and a decrease in the degree of proteinuria/albuminuria were noted after treatment. The patients had an easier time losing weight (body mass index
and waist circumference decreased; p<0.05) and decreased levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). None of the monitored patients had
cases of hypoglycemia or urinary tract infection. The number and/or doses of antihypertensive, hypouricemic and diuretic drugs were gradually reduced.
Conclusions: Using dapagliflozin in a standard dose of 10 mg/day in the complex therapy of patients with T2DM in combination with arterial hypertension and overweight
contributes not only to the normalization of blood pressure, but also to a reduction in body weight and waist circumference. The proposed therapy can be an alternative for the
treatment of patients with T2DM with concomitant overweight or obesity, arterial hypertension, with or without heart and/or renal failure as a first-line antidiabetic drug.
Додано/оновлено в НРАТ
2026-06-13
